GMP High Quingity Tranexamic Acid Injection Hemostatic Effect

• Transport Package: Carton
• Specification: Tranexamic Acid
• Trademark: Focus
• Origin: China
• Model NO.: Hemostatic effect
• HS Code: 3003209000
• Production Capacity: 100000000000boxes Per Year

Product Description

Product Parameters

 

Product name	Tranexamic acid injection
Main Ingredients	Tranexamic acid
Adaptation disease	Indications:  1. This product is mainly used for acute or chronic, localized or systemic primary fibrinolysis caused by all kinds of bleeding.  Secondary hyperfibrinolysis caused by disseminated intravascular coagulation is generally not used before heparinization.  2. Used for trauma or surgical bleeding of prostate, urethra, lung, brain, uterus, adrenal gland, thyroid gland and other organs rich in plasminogen activator.  3. Used as an antagonist of tissue plasminogen activator (T-PA), streptokinase and urokinase.  4. For artificial abortion, early placental abruption, stillbirth and amniotic fluid embolism caused by fibrinolytic bleeding, as well as pathological intrauterine local fibrinolytic hypermenorrhagia.  5. It is used for mild bleeding of central nervous diseases, such as subarachnoid hemorrhage and intracranial aneurysm hemorrhage. It is superior to other antifibrinolytic drugs for hemostasis, but the risk of complicated cerebral edema or cerebral infarction must be paid attention to.  6. For the treatment of hereditary angoneeurotic edema, can reduce the frequency and severity of its attack.  7. Hemophilia patients with active bleeding can be combined with this drug.  8. It is used to prevent or reduce bleeding after tooth extraction or oral surgery in factor VIII or factor deficiency hemophilia patients.
Dosage form	Liquid dosage form
Character	This product is a clear colorless liquid
Specification	(1)5 ml:0.25 g (2)5 ml:0.25g (3)10 ml:1 g (4)10 ml:1 g (5)2 ml:0.2 g (6)2 ml:0.2 g (7)5 ml:0.25 g  (8)5 ml:0.5 g
Usage and dosage	Intravenous injection or drip: 0.25-0.5g (1-2 tablets) at a time, 0.752g (3-8 tablets) a day.  Intravenous injection was diluted with 25% glucose solution and intravenous infusion was diluted with 5%-10% glucose solution.  To prevent bleeding before and after surgery, refer to the above doses.  When treating hemorrhage caused by primary fibrinolysis, the dose can be increased as appropriate.
Storage	Shading, airtight storage.
Origin	China
validity	24 months
Tatoo	Oral contraceptives, estrogen, or prothrombin complex concentrate may increase the risk of thrombosis when used with this product.
Notice	1. Careful with:  (1) It should be used with caution in patients with thrombosis tendency (such as acute myocardial infarction).  (2) As this product can lead to secondary pyelonephritis and ureteral clot obstruction, it should be used with caution when hemophilia or renal parenchymal lesion produces a large amount of hematuria.  2. This product should be used together with other clotting factors (such as factor ), so as to guard against thrombosis.  It is generally considered appropriate to use this product 8 hours after the use of clotting factors.  3. This product is generally not used alone for secondary fibrinolytic bleeding caused by disseminated intravascular coagulation to prevent further thrombosis and affect organ function, especially in acute renal failure.  If necessary, this product should be used on a heparinization basis.  4. Heparin is safer than this product in the treatment of hypofibrinogen bleeding caused by intrauterine stillbirth.  5. In the case of chronic renal insufficiency, the dosage of this drug should be reduced, because the urine concentration is often high after administration.  6. When treating prostate bleeding, the dosage of this product should also be reduced.  7. This product is contraindicated with penicillin or blood infusion.  8. Eye examination and monitoring (such as visual acuity test, visual, visual field and fundus) should be conducted for those who must continue using the product for a long time.
	[Adverse reactions]  The adverse reaction of this product was less than that of 6-amino caproic acid.  1. Occasionally intracranial thrombosis and hemorrhage caused by drug overdose.  2. Diarrhea, nausea and vomiting may occur. 3. Less commonly, menstrual discomfort (caused by blood clotting during menstruation).  4. As this product can enter the cerebrospinal fluid, there may be blurred vision, headache, dizziness, fatigue and other central nervous system symptoms after injection, especially related to the injection speed, but it is rare.

   

Detailed Photos

 

Packaging & Shipping

This product is colorless clear liquid, belongs to the injection, please closed shade preservation.
The main ingredient is tranexamic acid, mainly used for hemostasis.

We use low borosilicate glass ampoules, available in brown and colorless colors.  

We can provide the following specifications on the package:  
(1) 5 ml: 0.25g, 5 PCS/box;  
(2) 5 ml: 0.25g, 10 PCS/box;  
(3) 10 ml: 1 g, 5 PCS/box;  
(4) 10 ml: 1 g, 2 PCS/box;  
(5) 2 ml: 0.2g, 5 PCS/box;  
(6) 2 ml: 0.2g, 10 PCS/box;  
(7) 5 ml: 0.25g, 6 PCS/box;  
(8) 5 ml: 0.5 g, 6 PCS/box;   

Usage and precautions please refer to the above table or follow the doctor's advice.  

To get more information, just feel free to contact with us.  Thanks.